tbuckley/cabot-search huggingface dataset:
Correspondence on ‘Increased risk of systemic lupus erythematosus in patients with autoimmune haemolytic anaemia’
Authors: Hong Huang, Zhuoli Zhang
Journal: Annals of the Rheumatic Diseases (2020)

With great interest, we read the recent article by Mo et al regarding the association between autoimmune haemolytic anaemia (AIHA) and the subsequent development of systemic lupus erythematosus (SLE) based on a nationwide population-based cohort.1 In this study, the authors found that patients with AIHA had an increased risk of SLE (HR 54.67; 95% CI 22.33–133.89). We appreciate Mo et al ’s work on this group of patients with a high risk of developing SLE, which should be more carefully managed in the future, however, we would like to address some points.

First, previous studies have indicated that patients with childhood-onset SLE were more likely …
COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients
Authors: Moayed Ibrahim, Priya Pal, Alex Niu, Kevin Zwezdaryk, Elise Tatje, Leta Ko, Ishwaria Satyavarap, Wallace Jones, Adeem Nachabe, Alfred Luk, David M Mushatt, Karin Halvorson, Joshua Denson, Francesco Simeone, Charles Smith, Gaynelle Davis, Sukhmani Gill, April McDougal, Aniko Vigh, Tim Peterson, Bo Ning, Tony Hu, Francisco Socola, Hana Safah, Nakhle S. Saba
Journal: Blood (2020)
SAT0091 Effects of joint lavage and hyaluronic acid infiltration in patients with osteoarthritis of the knee
Authors: MA Caracuel, MC Muñoz-Villanueva, A Escudero, R Veroz, G Frias, J Vacas, C Perez, M Romero, V Perez, J Gonzalez, FG Martinez, E Collantes
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Infiltration with hyaluronic acid (HA) and joint lavage (JL) have recently been proposed as local treatments for osteoarthritis of the knee. Joint lavage is a therapeutic treatment involving passing cold sterile 0.9% saline through the knee joint in order to have the liquid reach the inside of the joint capsule. <h3>Objectives</h3> To evaluate the efficacy of joint lavage and intraarticular infiltration with hyaluronic acid, alone and in combination (JLHA), as symptomatic treatments for knee osteoarthritis. <h3>Methods</h3> An overall 37 patients (8 males and 29 females) aged 43–85 years with knee osteoarthritis of radiological grade II on the Kellgren scale were randomly classified into three thera-peutic groups, namely: JL (n = 14), HA (n = 10) and JLHA (n = 13). The patients in group JL received joint lavage, on day 0 only; those in group JLHA were subjected to joint lavage on day 0 and to infiltration on days 0, 7, 14, 21 and 28. Outcome measures evaluated at baseline, at days 7 and 30 included severity of pain (VAS), Global status (VAS) and Lequesne?s functional index. <h3>Results</h3> The results of the Global Status difference from baseline are summarised in the following Table 1: <h3>Conclusion</h3> Our results suggest significant differences between the tested treatments, Joint lavage alone and followed by infiltration with the hyaluronic acid is more effective than local infiltration with hyaluronic acid alone.
Abstract 13370: Echocardiographic Screening of Pregnant Women by Non-Physicians With Remote Interpretation in Primary Care: Data From the PROVAR+ Study
Authors: Bruno R Nascimento, Andrea Z Beaton, Maria Do Carmo P Nunes, Kaciane K Oliveira, Adriana C Diamantino, Lara C Rabelo, Marcia Barbosa, Alison T Reese, Susana P Reis, Clara L Fraga, Breno D Rezende, Waydder Antônio A Costa, Antonio L Ribeiro, Craig A Sable
Journal: Circulation (2019)

Introduction: Delays in diagnosis of heart disease (HD) associated with pregnancy may impact clinical outcomes. We aimed to evaluate the feasibility of integrating screening echocardiography (echo)...
Personal-Level Protective Actions Against Particulate Matter Air Pollution Exposure: A Scientific Statement From the American Heart Association
Authors: Sanjay Rajagopalan, Michael Brauer, Aruni Bhatnagar, Deepak L. Bhatt, Jeffrey R. Brook, Wei Huang, Thomas Münzel, David Newby, Jeffrey Siegel, Robert D. Brook
Journal: Circulation (2020)

Since the publication of the last American Heart Association scientific statement on air pollution and cardiovascular disease in 2010, unequivocal evidence of the causal role of fine particulate matter air pollution (PM2.5, or particulate matter ≤2.5 μm in diameter) in cardiovascular disease has emerged. There is a compelling case to provide the public with practical personalized approaches to reduce the health effects of PM2.5. Such interventions would be applicable not only to individuals in heavily polluted countries, high-risk or susceptible individuals living in cleaner environments, and microenvironments with higher pollution exposures, but also to those traveling to locations with high levels of PM2.5. The overarching motivation for this document is to summarize the current evidence supporting personal-level strategies to prevent the adverse cardiovascular effects of PM2.5, guide the use of the most proven/viable approaches, obviate the use of ineffective measures, and avoid unwarranted interventions. The significance of this statement relates not only to the global importance of PM2.5, but also to its focus on the most tested interventions and viable approaches directed at particulate matter air pollution. The writing group sought to provide expert consensus opinions on personal-level measures recognizing the current uncertainty and limited evidence base for many interventions. In doing so, the writing group acknowledges that its intent is to assist other agencies charged with protecting public health, without minimizing the personal choice considerations of an individual who may decide to use these interventions in the face of ongoing air pollution exposure.
Laparoscopic versus open surgery for gastrointestinal stromal tumor in esophagogastric junction: A multi-center, retrospective cohort analysis with propensity score matching.
Authors: Wenjun Xiong, Tao Chen, Xingyu Feng, Yuting Xu, Jin Wan, Rui Zhou, Yong Li, Guoxin Li, Wei Wang
Journal: Journal of Clinical Oncology (2020)

11534 Background: Laparoscopic resection is increasingly performed for Gastrointestinal stromal tumor (GIST). Nevertheless, laparoscopic approach for the GIST located in the esophagogastric junction (EGJ-GIST) represent a surgical challenge. This study aims to investigate the efficacy of laparoscopic surgery and open procedure for EGJ-GIST through the propensity score matching (PSM) method. Methods: Between April 2006 and April 2018, 1824 patients underwent surgery were finally diagnosed with primary gastric GIST at four medical centers in South China. EGJ-GIST was defined as a GIST with an upper border of less than 5 cm from the EG line. Among them, 228 patients were identified and retrospectively reviewed with regard to clinicopathological characteristics, operative information and long-term outcomes. The PSM methods was used to eliminate the selection bias. Results: After PSM, 102 cases, consisted of 51 laparoscopic (LA) and 51 open surgery (OP), were enrolled. The match factors contained year of surgery, gender, age, BMI, tumor size, mitotic rate, recurrence risk and adjuvant tyrosine kinase inhibitors treatment. The LA group was superior to the OP group in operative time (108.5±56.5 vs. 169.3±79.0 min, P &lt;0.001), blood loss (54.6±81.9 vs. 104.9±156.4 ml, P = 0.042), time to liquid intake (3.1±1.8 vs. 4.3±2.2 d, P = 0.003), hospital stay (6.0±2.3 vs. 9.9±8.1, P = 0.001), and postoperative complication (5.9% vs. 25.5%, P = 0.006). The median follow-up was 55 (range, 2-153) months in the entire cohort. No significant differences were detected in either the relapse-free survival (RFS, P = 0.109) or overall survival (OS, P = 0.113) between two groups. The 1-, 3-, and 5-year RFS in the LA and OP groups were 100.0%, 95.5%, 91.0% and 100.0%, 90.8%, 85.7%, respectively. The 1-, 3-, and 5-year OS in the LA and OP group were 100%, 95.6%, 91.3% and 100.0%, 91.1%, 85.4%, respectively. Conclusions: Laparoscopic surgery for EGJ-GIST is associated with the advantages of shorter operative time, reduced blood loss, shorter time to liquid intake and shorter length of stay, all without compromising post-operative outcomes and long-term survival.
Thrombotic Events in COVID-19 Patients and Its Comparison with Other Non-Sars-Cov-2 Respiratory Viruses
Authors: Jing Yuan Tan, Chuen Wen Tan, Wan Hui Wong, Edwin Philip Conceicao, Ian Matthias Ng, May Anne Cheong, Jenny Guek-Hong Low, Heng Joo Ng, Lai Heng Lee
Journal: Blood (2020)
Abstract 281: Human Atrial Extracellular Matrix Drives Differentiation of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Toward an Atrial Phenotype
Authors: Fernanda Mesquita, Jacquelynn Morrissey, Yutao Xi, Gustavo Monnerat, Fabio Nogueira, Gilberto Domont, Luiz Sampaio, Camila Hochman-mendez, Doris A Taylor
Journal: Circulation Research (2020)

Extracellular matrix (ECM) can directly modulate cell proliferation, migration and differentiation by mediating diverse growth factors and signaling interactions. Protocols for cardiomyocyte differentiation of induced pluripotent stem cells (iPSCs) that recapitulate cardiac development frequently result in a mixed cardiac cell population dominated overwhelmingly by ventricular-like cells. Utilizing the inherent biological capabilities of decellularized ECM (dECM) from human myocardium, we developed a method for committing human iPSCs to an atrial-like cell phenotype. We employed a modified decellularization method to generate small particles (125-500 μm) of human atrial and ventricular dECM. The particles presented a fractal dimension (1.63 and 1.71) that suggested self-similarity across particle sizes of both atrial and ventricular dECM. Quantifications of DNA (3.37±0.50 and 2.77±0.62% of cadaveric), GAG (0.44±0.08 and 0.59±0.13 μg/mg), and SDS (2.46±1.20 and 2.91±2.53 μg/mg) validated the absence of difference of atrial and ventricular dECM. Proteomic profiling revealed dECM chamber-specific clustered populations. Ventricular and atrial dECM segregated into ventricular and atrial parts based on component 1 (19.5%) and component 2 (13.9%). A total of 14% of atrial proteins were matrisome atrial-related and 13% of ventricle proteins were matrisome ventricular-related. Myocytes differentiated in the presence of atrial dECM showed similar differentiation efficiency (66.6±10.2 vs 65.5±12.7% of cTNT) and, importantly, increased atrial markers, as confirmed by qPCR (SLP and COUPF-I) and flow cytometry (43.5%±12.7% vs 23.9%±10.8% of MLC2a) in comparison to control. We observed an increase in atrial cells (38.4% vs 14.8%) by action potential duration (APD), with statistical differences in cAPD10 (57.1±20.2 vs 104.4±48.7 ms) and cAPD20 (76.2±22 vs 126±47.4 ms). Altogether, we demonstrate that human atrial ECM retains cues to drive cardiac differentiation to an atrial fate, doubling the number of atrial cells with a functional atrial phenotype. These findings are a critical step toward generating sufficient quantities of atrial cells, which can be used for chamber-specific cardiac disease modeling and drug development.
Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure
Authors: Alejandro Luna, Natalia Estrada, Concepcion Boque, Blanca Xicoy, Pilar Giraldo, Anna Angona, Alberto Alvarez-Larrán, Fermin Sanchez-Guijo, María José Ramírez, Juan M. Alonso-Domínguez, Elvira Mora, Patricia Vélez, Ana Rosell, Mercedes Colorado Araujo, Beatriz Cuevas, Miguel Sagüés, Montserrat Cortes, Manuel Perez Encinas, Luis Felipe Casado Montero, Melania Moreno Vega, Luis Serrano, Valle Gomez, Carmen Garcia-Hernandez, Sunil Lakhwani Lakhwani, Antonio Paz Coll, Raquel de Paz, Sara Suarez-Varela, Andrés Fernandez-Ruiz, Raul Perez Lopez, Almudena Ortiz-Fernández, Antonio Jiménez-Velasco, Valentín Garcia-Gutiérrez
Journal: Blood (2020)
CD33 Targeting Primary CAR-NK Cells Generated By CRISPR Mediated Gene Insertion Show Enhanced Anti-AML Activity
Authors: Meisam Naeimi Kararoudi, Shibi Likhite, Ezgi Elmas, Maura Schwartz, Kinnari Sorathia, Kenta Yamamoto, Nitin Chakravarti, Branden S Moriarity, Kathrin Meyer, Dean Anthony Lee
Journal: Blood (2020)
Precise targeting of miR-141/200c cluster in chondrocytes attenuates osteoarthritis development
Authors: Ming-Liang Ji, Hua Jiang, Fei Wu, Rui Geng, Li kun Ya, Yu Cheng Lin, Ji Hao Xu, Xiao Tao Wu, Jun Lu
Journal: Annals of the Rheumatic Diseases (2020)

Despite preclinical studies involving miRNA therapeutics conducted in osteoarthritis (OA) over the years, none of these miRNAs have yet translated to clinical applications, owing largely to the lack of efficient intra-articular (IA) delivery systems. Here, we investigated therapeutic efficacy of the chondrocyte-specific aptamer-decorated PEGylated polyamidoamine nanoparticles (NPs)-based miRNAs delivery for OA.The role of miR-141/200c cluster during skeletal and OA development was examined by miR-141/200cflox/flox mice and Col2a1-CreERT2; miR-141/200cflox/flox mice. Histological analysis was performed in mouse joints and human cartilage specimens. Chondrocyte-specific aptamer-decorated NPs was designed, and its penetration, stability and safety were evaluated. OA progression was assessed by micro-CT analysis, X-ray and Osteoarthritis Research Society International scores after destabilising the medial meniscus surgery with miR-141/200c manipulation by NPs IA injection. Mass spectrometry analysis, molecular docking and molecular dynamics simulations were performed to investigate the interaction between aptamer and receptor.Increased retention of NPs inside joint space is observed. The NPs are freely and deeply penetrant to mice and human cartilage, and unexpectedly persist in chondrocytes for at least 5 weeks. OA chondrocytes microenviroment improves endo/lysosomal escape of microRNAs (miRNAs). Therapeutically, IA injection of miR-141/200c inhibitors provides strong chondroprotection, whereas ectopic expression of miR-141/200c exacerbates OA. Mechanistically, miR-141/200c promotes OA by targeting SIRT1, which acetylates histone in the promoters of interleukin 6 (IL-6), thereby activating IL-6/STAT3 pathway.Our findings indicate that this nanocarrier can optimise the transport kinetics of miR-141/200c into chondrocytes, fostering miRNA-specific disease-modifying OA drugs development.
SAT0094 Celecoxib does not increase the risk of cardiac failure, oedema, or hypertension compared to nsaids: results from success 1, a double blind, randomised trial in 13,274 oa patients
Authors: A Whelton, G Singh, W White, J Fort, A Bello
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> COX-2 specific inhibitors have been shown to significantly reduce the risk of gastrointestinal complications compared to conventional NSAIDs, while providing equivalent efficacy. However, some recent studies have raised concerns about the cardiovascular and renal safety profile of COX-2 inhibitors. In a previous study of 7,968 patients in North America, celecoxib at supratherapeutic doses (800 mg/d) was shown not to increase the risk of hypertension, congestive heart failure, or renal adverse events compared to therapeutic doses of ibuprofen and diclofenac. <h3>Objectives</h3> To compare the risk of congestive heart failure, oedema, and hypertension in OA patients treated with celecoxib at 200 or 400 mg per day compared to patients taking therapeutic doses of diclofenac and naproxen in a multinational, double-blind randomised trial (SUCCESS-1 in OA). <h3>Methods</h3> A total of 13,274 patients from 1142 sites in 39 countries in Europe, South Africa, Asia, Latin America, and the United States and Canada were enrolled in the SUCCESS-1 trial. Patients were randomly assigned to fixed treatment regimens of celecoxib 200 mg per day, celecoxib 400 mg per day, or NSAIDs (naproxen 1000 mg per day in the US and Canada and diclofenac 100 mg per day in other regions). <h3>Results</h3> Of the 13,194 patients randomised, 4421 and 4429 patients received 200 or 400 mg per day of celecoxib respectively, 914 patients received 1000 mg per day of naproxen, and 3510 patients received 100 mg per day of diclofenac. Patients were mostly female (67%), and 42% were 65 years or older (mean age: 62 years). Previous cardiovascular disease was comparable in each intent-to-treat group (p = 0.25). ASA use was 7.9% and 8.0% at baseline, in the celecoxib and NSAID groups, respectively. The number of patients with cardiovascular and renal events adverse events is shown in the Table 1 below: <h3>Conclusion</h3> SUCCESS 1 provides additional evidence that celecoxib is associated with low incidence of cardiovascular or renal toxicity that is comparable to conventional NSAIDs. Sponsored by Pharmacia Corporation and Pfizer Inc.
COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience
Authors: Lindsay Wilde, Adam F. Binder, Matthew Carabasi, Joanne Filicko-O'Hara, John L. Wagner, Onder Alpdogan, Margaret Kasner, Thomas R. Klumpp, Ubaldo Martinez-Outschoorn, Neil Palmisiano, Gina Keiffer, Dolores Grosso, Michael Millenson, Amy R. MacKenzie, Allison Zibelli, Neal Flomenberg, Pierluigi Porcu, Usama Gergis
Journal: Blood (2020)
Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Authors: Jeffrey E. Rubnitz, Thomas B. Alexander, Theodore W. Laetsch, Seong Lin Khaw, Vinod A. Pullarkat, Joseph T. Opferman, Kathryn G Roberts, Lindsey Rosenwinkel, Bo Tong, John C. Pesko, Mohamed Badawi, Deeksha Vishwamitra, Su Young Kim, Charles G Mullighan, Norman J. Lacayo
Journal: Blood (2020)
Plasmacytoid Dendritic Cells Surveil Megakaryocyte Sialic Acid to Regulate Thrombopoiesis
Authors: Melissa M. Lee-Sundlov, Robert Burns, Renata Grozovsky, Silvia Giannini, Leonardo Rivadeneyra, Yongwei Zheng, Simon Glabere, Walter H. Kahr, Reza Abdi, Demin Wang, Karin M. Hoffmeister
Journal: Blood (2020)
Design and Functional Validation of a Mutant Variant of the LncRNA <i>HOTAIR</i> to Counteract Snail Function in Epithelial-to-Mesenchymal Transition
Authors: Cecilia Battistelli, Sabrina Garbo, Veronica Riccioni, Claudia Montaldo, Laura Santangelo, Andrea Vandelli, Raffaele Strippoli, Gian Gaetano Tartaglia, Marco Tripodi, Carla Cicchini
Journal: Cancer Research (2020)

Abstract HOTAIR is a lncRNA overexpressed in several epithelial cancers and strongly correlated with invasion. This lncRNA was proven a pivotal element of the epithelial-to-mesenchymal transition (EMT), a transdifferentiation process triggering metastasis. Snail, master inducer of EMT, requires HOTAIR to recruit EZH2 on specific epithelial target genes (i.e., HNF4α, E-cadherin, and HNF1α) and cause their repression. Here, we designed a HOTAIR deletion mutant form, named HOTAIR-sbid, including the putative Snail-binding domain but depleted of the EZH2-binding domain. HOTAIR-sbid acted as a dominant negative of the endogenous HOTAIR. In both murine and human tumor cells, HOTAIR-sbid impaired the ability of HOTAIR to bind Snail and, in turn, trigger H3K27me3/EZH2-mediated repression of Snail epithelial target genes. Notably, HOTAIR-sbid expression was proven to reduce cellular motility, invasiveness, anchorage-independent growth, and responsiveness to TGFβ-induced EMT. These data provide evidence on a lncRNA-based strategy to effectively impair the function of a master EMT-transcriptional factor. Significance: This study defines an innovative RNA-based strategy to interfere with a pivotal function of the tumor-related lncRNA HOTAIR, comprising a dominant negative mutant that was computationally designed and that impairs epithelial-to-mesenchymal transition.
Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01
Authors: Scott Howard, Prashant Ramachandran Nair, Himanshu Grover, Anuj Tyagi, Pallavi Kumari, Samiksha Avinash Prasad, Upasana Mitra, Deepak Anil Lala, Humera Azam, Neha Gupta, Subrat Mohapatra, Poornachandra G, Nirjhar Mundkur, Michele Dundas Macpherson, Shweta Kapoor
Journal: Blood (2020)
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study
Authors: Max J. Gordon, Andy Kaempf, Andrea Sitlinger, Tareq Salous, Hamood Alqahtani, Michael C. Churnetski, Paul Wisniewski, Xavier Issac Rivera, Krish Patel, Daniel O. Persky, Jonathon B. Cohen, Michael Y. Choi, Brian T. Hill, Mazyar Shadman, Deborah M. Stephens, Danielle M. Brander, Byung Park, Alexey Danilov
Journal: Blood (2020)
A First Large Statewide Population Based Study Evaluating Racial Differences in Treatment and Survival between Hispanics and Non-Hispanics with Diffuse Large B Cell Lymphoma (DLBCL)
Authors: Daniela Hernandez, Carolina Velez-Mejia, Joel E Michalek, Qianqian Liu, Adolfo Enrique Diaz Duque
Journal: Blood (2020)
Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms
Authors: Olga Dashevsky, Ricardo De Matos Simoes, Ryosuke Shirasaki, Michal Sheffer, Eugen Dhimolea, Sara Gandolfi, Huihui Tang, Sondra L. Downey-Kopyscinski, Megan Bariteau, Jeffrey Sorrell, Brian Glassner, John Doench, Larry H. Boise, Jonathan D. Licht, Aedin Culhane, William C. Hahn, Francisca Vazquez, Aviad Tsherniak, Constantine S. Mitsiades
Journal: Blood (2020)
Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia
Authors: Sanaz Ghafouri, Christopher Walthers, Mobina Roshandell, Brenda Ji, Jacqueline Trent, Jia Ming Chen, Jacob Naparstek, Monica Mead, John M. Timmerman, Yvonne Chen, Sarah Larson
Journal: Blood (2020)
Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone
Authors: Larysa Sanchez, Xavier Leleu, Jennifer Beaumont, Hailin Yu, Stacie Hudgens, Holger W Auner, Hang Quach, Sosana Delimpasi, Ivan Spicka, Luděk Pour, Meletios A Dimopoulos, Halyna Pylypenko, Vadim A Doronin, Ganna Usenko, Roman Hajek, Reuben Benjamin, Christopher P. Venner, Mamta Garg, Don A. Stevens, Sundar Jagannath, Philippe Moreau, Moshe Levy, Nizar J. Bahlis, Thierry Facon, Yi Chai, Xiwen Ma, Shijie Tang, Hoyee Leong, Jatin J. Shah, Sharon Shacham, Michael G Kauffman, Paul G. Richardson, Sebastian Grosicki
Journal: Blood (2020)
Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study
Authors: Rosemary Anne Harrup, Carolyn Owen, James D'Rozario, Tadeusz Robak, Arnon P. Kater, Marco Montillo, Javier de la Serna, Marek Trněný, Su Young Kim, Edward Bataillard, Marcus Lefebure, Michelle Boyer, John F. Seymour
Journal: Blood (2020)
Abstract 13737: Rethink That Tap - Paracentesis in Patients With Ascites and Systolic Heart Failure is Not Associated With Improve Renal Function or Reduction in All-Cause Mortality
Authors: Yuxiang Wang, Wayne L Miller
Journal: Circulation (2019)

Introduction: In patients with heart failure, the relationship between systolic dysfunction, intra-abdominal pressure (IAP), and renal function are only beginning to be understood. Limited single c...
KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma
Authors: Saad Z. Usmani, Jesus G. Berdeja, Anna Truppel-Hartmann, Marie-Laure Casadebaig, Honeylet Wortman-Vayn, Suresh G. Shelat, Steven Novick, Nina Shah
Journal: Blood (2020)
Similar Molecular Pattern in Therapy Related Acute Myeloid Leukemia in Patients Treated with Purp Inhibitors for Metastatic Ovarian Cancer
Authors: Patrizia Chiusolo, Claudia Marchetti, Monica Rossi, Gessica Minnella, Mirella Di Stefano, Anna Fagotti, Giuseppe Leone, Giovanni Scambia, Simona Sica
Journal: Blood (2020)